News headlines about Mediwound (NASDAQ:MDWD) have trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mediwound earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.0786575072449 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several research firms have recently weighed in on MDWD. ValuEngine downgraded Mediwound from a “sell” rating to a “strong sell” rating in a research report on Thursday. SunTrust Banks set a $9.00 price objective on Mediwound and gave the company a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research cut Mediwound from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. Finally, Oppenheimer set a $10.00 price objective on Mediwound and gave the company a “buy” rating in a report on Friday, December 8th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.13.

Mediwound (NASDAQ:MDWD) opened at $4.20 on Monday. Mediwound has a 1-year low of $3.56 and a 1-year high of $8.25. The stock has a market capitalization of $113.60, a price-to-earnings ratio of -4.29 and a beta of 0.15.

TRADEMARK VIOLATION WARNING: “Mediwound (MDWD) Given Coverage Optimism Score of 0.19” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Insider Buying and Selling by Quarter for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with's FREE daily email newsletter.